Introduction
Avatrombopag is an oral thrombopoietin receptor agonist used to increase platelet production in specific patients with thrombocytopenia. It works by stimulating the thrombopoietin receptor, a biological receptor involved in the development and maturation of platelet-producing cells in the bone marrow.
Avapag 20 mg is identified on this website as a product containing avatrombopag. The clinical information on this page focuses on the active ingredient and its established medical uses. It should not be interpreted as confirmation of the clinical performance, regulatory authorization or manufacturer-specific characteristics of the Avapag-branded product.
Thrombocytopenia refers to a lower-than-normal platelet count. Platelets are essential for normal blood clotting, and a significant reduction can increase the risk of bruising and bleeding. The causes of thrombocytopenia vary, so appropriate treatment depends on the underlying condition and the patient’s individual medical circumstances.
Avatrombopag has established uses in two important adult treatment settings:
- Thrombocytopenia associated with chronic liver disease in adults scheduled to undergo a procedure.
- Chronic immune thrombocytopenia in adults who have had an insufficient response to previous treatment.
The treatment objective, dosing schedule and monitoring requirements differ between these indications.
1. Pharmacological Classification
Avatrombopag belongs to the pharmacological class known as thrombopoietin receptor agonists, commonly abbreviated as TPO-RAs.
Thrombopoietin is a naturally occurring hormone that helps regulate platelet production. It interacts with receptors on bone marrow cells involved in the development of megakaryocytes.
Megakaryocytes are large cells that mature in the bone marrow and release platelets into the bloodstream. By activating the thrombopoietin receptor, avatrombopag supports this platelet-production pathway.
Unlike medicines that directly supply platelets, avatrombopag works by stimulating the body’s own platelet-producing cells.
2. Mechanism of Action
Avatrombopag acts as an agonist of the thrombopoietin receptor, also known as c-Mpl.
Its mechanism of action involves the following processes:
Thrombopoietin receptor interaction: Avatrombopag binds to and activates the thrombopoietin receptor on platelet-producing bone marrow cells.
Intracellular signaling: Receptor activation stimulates intracellular signaling pathways involved in the growth and development of megakaryocyte precursor cells.
Megakaryocyte development: These precursor cells develop and mature into megakaryocytes.
Platelet production: Mature megakaryocytes release platelets into the bloodstream.
Increase in platelet count: The increased platelet production can result in a higher circulating platelet count.
The degree of response differs between patients. Treatment is therefore guided by platelet measurements and the clinical circumstances of the individual.
3. Clinical Use in Chronic Liver Disease
Chronic liver disease can be associated with thrombocytopenia through several biological mechanisms.
The liver plays an important role in producing thrombopoietin, a hormone involved in regulating platelet production. Liver disease may also be associated with an enlarged spleen, which can increase platelet sequestration and contribute to lower circulating platelet counts.
For certain adults with chronic liver disease and thrombocytopenia who are scheduled to undergo a medical procedure, avatrombopag may be prescribed to increase platelet counts before the procedure.
Treatment objective
The main objective is to increase the platelet count to an appropriate level before the planned procedure.
The treatment may help reduce the need for platelet transfusion in appropriately selected patients. However, it does not eliminate every procedural bleeding risk or guarantee that a transfusion will not be needed.
Treatment considerations
Important clinical considerations include:
- Baseline platelet count.
- Type and timing of the planned procedure.
- Underlying liver disease.
- Previous history of thrombosis.
- Other medical conditions.
- Current medicines.
- Response to treatment.
The treatment schedule is based on the patient’s platelet count and the applicable prescribing information.
4. Clinical Use in Chronic Immune Thrombocytopenia
Chronic immune thrombocytopenia, or chronic ITP, is an immune-mediated condition characterized by reduced platelet levels.
In ITP, the immune system mistakenly targets platelets, leading to increased platelet destruction and, in some cases, impaired platelet production.
Patients may experience bruising, petechiae, nosebleeds, gum bleeding or other bleeding symptoms. The severity varies considerably.
Avatrombopag may be used in specified adults with chronic ITP who have had an insufficient response to previous treatment.
Treatment objective
The primary treatment objective is to increase platelet counts to a level that helps reduce the risk of clinically significant bleeding.
Avatrombopag stimulates platelet production, helping compensate for the reduced platelet availability associated with the condition.
Ongoing treatment assessment
Patients receiving avatrombopag for chronic ITP may require regular platelet-count testing.
The healthcare professional evaluates the response and determines whether the dose should be maintained, adjusted or interrupted according to the applicable prescribing information.
Avatrombopag helps manage platelet levels but does not necessarily eliminate the underlying autoimmune process.
5. Pharmacodynamic Effects
Pharmacodynamics describes how a medicine affects the body, including its biological activity and measurable treatment effects.
Clinical pharmacology information for avatrombopag indicates that its effect on platelet counts is related to the administered dose and drug exposure.
Platelet response
In adults receiving the reference avatrombopag tablet product, an increase in platelet count was observed within approximately 3–5 days after starting treatment. The peak effect was generally observed around 10–13 days.
After treatment ends, platelet counts gradually decrease toward their baseline levels.
These observations describe the reference product’s clinical pharmacology and should not be interpreted as a guaranteed response time for every patient or as product-specific clinical evidence for Avapag.
Importance of an appropriate platelet response
The objective of treatment is to achieve an appropriate platelet count for the patient’s medical condition.
Increasing platelet levels beyond the required range is not the treatment goal. Excessively high platelet counts may contribute to thrombotic complications.
Healthcare professionals therefore use platelet measurements to assess treatment response and guide dosing decisions.
6. Clinical Pharmacokinetics
Pharmacokinetics describes how a medicine is absorbed, distributed, metabolized and eliminated by the body.
The pharmacokinetic properties of avatrombopag help explain its oral administration and the importance of considering other medicines during treatment.
Absorption
Avatrombopag is an orally bioavailable small-molecule medicine. After oral administration, the active ingredient is absorbed into the bloodstream.
The reference tablet product is administered with food according to its prescribing information. Patients should follow the instructions provided for their specific medicine.
Distribution
After absorption, avatrombopag enters the systemic circulation and becomes available to interact with thrombopoietin receptors.
Its distribution and exposure contribute to the pharmacological response.
Metabolism
Avatrombopag undergoes metabolism involving liver enzyme pathways, including CYP2C9 and CYP3A4.
Medicines that affect these enzymes may alter avatrombopag exposure. This is particularly important for patients receiving chronic ITP treatment.
Elimination
Avatrombopag and its metabolites are eliminated through the body’s normal drug-clearance processes. Patient-specific factors and other medicines may influence exposure.
A healthcare professional should review relevant medical conditions and concurrent medications before treatment.
7. Clinical Evidence and Treatment Research
The clinical development of avatrombopag has included studies in adults with chronic liver disease-associated thrombocytopenia and adults with chronic immune thrombocytopenia.
These studies evaluated platelet-count responses and clinically relevant treatment outcomes.
Studies in chronic liver disease
Clinical studies evaluated avatrombopag in adults with chronic liver disease and low platelet counts who were scheduled to undergo procedures.
The research assessed whether treatment could increase platelet counts and reduce the need for platelet transfusion or rescue procedures related to bleeding.
The findings supported the use of the reference avatrombopag product for the relevant adult indication.
Studies in chronic immune thrombocytopenia
Clinical research also evaluated avatrombopag in adults with chronic ITP who had an insufficient response to previous treatment.
Researchers assessed platelet-count responses, the ability to maintain platelet levels and the safety of treatment.
These studies contributed to the clinical evidence supporting avatrombopag as a treatment option for specified adults with chronic ITP.
Understanding clinical evidence
Clinical trial results apply to the studied medicine, patient populations, treatment regimens and study conditions.
They should not automatically be interpreted as proof that every branded product containing the same active ingredient has undergone identical clinical trials.
Avapag-specific clinical equivalence, bioequivalence or regulatory evidence should only be claimed when supported by appropriate product documentation.
8. Platelet Monitoring During Treatment
Platelet-count monitoring is an essential part of avatrombopag treatment.
The monitoring schedule depends on the medical indication and the patient’s response.
Before treatment
Before starting therapy, healthcare professionals may assess:
- Baseline platelet count.
- Underlying cause of thrombocytopenia.
- Medical history.
- Previous treatment response.
- History of blood clots.
- Current prescription medicines.
- Planned medical procedures, where applicable.
During chronic liver disease treatment
For adults receiving avatrombopag before a scheduled procedure, platelet counts are assessed before treatment and on the day of the procedure according to the applicable prescribing information.
The purpose is to evaluate the platelet response and determine whether an appropriate increase has occurred.
During chronic ITP treatment
For adults receiving ongoing treatment for chronic ITP, platelet counts are generally assessed frequently after treatment begins.
The reference-product prescribing information recommends weekly monitoring until a stable response is achieved, followed by less frequent monitoring as appropriate.
Platelet counts should also be monitored after treatment discontinuation according to the prescribing information.
Why monitoring matters
Monitoring helps healthcare professionals:
- Assess the effectiveness of treatment.
- Identify an excessive platelet response.
- Guide dose adjustments.
- Evaluate the need for continued treatment.
- Identify potential safety concerns.
Patients should not change their treatment schedule based on an individual blood-test result without medical guidance.
9. Important Clinical Safety Considerations
Although avatrombopag can increase platelet production, treatment is associated with important safety considerations.
Thrombotic and thromboembolic complications
Thrombopoietin receptor agonists have been associated with thrombotic and thromboembolic complications.
A thrombotic event occurs when a blood clot develops inside a blood vessel. A thromboembolic event occurs when a clot or part of a clot travels through the circulation and blocks another blood vessel.
Patients with chronic liver disease or chronic ITP may have additional factors that influence their clotting risk.
Possible warning symptoms include:
- Sudden chest pain.
- Difficulty breathing.
- Pain or swelling in one leg.
- Sudden weakness or numbness.
- Sudden changes in vision.
- Severe or unusual headache.
These symptoms require prompt medical assessment.
Excessive platelet increases
The goal of treatment is not to normalize platelet counts or increase them without limitation.
The lowest effective treatment regimen should be used according to the applicable prescribing information and medical assessment.
Drug interactions
Certain medicines can affect avatrombopag exposure through CYP2C9 and CYP3A4 enzyme pathways.
Moderate or strong dual inhibitors or inducers of these enzymes may require special consideration, particularly for chronic ITP treatment.
Patients should provide their healthcare professional with a complete list of prescription medicines, over-the-counter products and supplements.
10. Special Patient Considerations
Treatment decisions should consider the patient’s overall health and individual risk factors.
Patients with chronic liver disease
The severity of liver disease, baseline platelet count and planned procedure should be considered before treatment.
Patients with a history of blood clots
A previous thrombotic event may be relevant when assessing whether avatrombopag is appropriate.
Pregnant patients
Available product information warns that avatrombopag may cause fetal harm. Pregnancy status and potential pregnancy should be discussed with a healthcare professional before treatment.
Breastfeeding patients
The reference-product prescribing information advises against breastfeeding during treatment. Patients should discuss appropriate options with their healthcare professional.
Older adults
Treatment decisions for older adults should consider overall health, other medical conditions and concurrent medicines.
11. Clinical Limitations
Avatrombopag is not appropriate for every patient with thrombocytopenia.
It does not treat every underlying cause of low platelet counts, and it does not replace other necessary medical treatment.
Important limitations include:
- It is intended for specific medical indications.
- Treatment response varies between individuals.
- It requires platelet-count monitoring.
- It may increase the risk of thrombotic complications.
- It does not guarantee the prevention of bleeding.
- It does not eliminate the underlying immune process in chronic ITP.
- It should not be used without appropriate medical supervision.
The decision to prescribe avatrombopag should be based on an individual clinical assessment.
12. Clinical Summary
| Clinical area | Key information |
|---|---|
| Active ingredient | Avatrombopag |
| Pharmacological class | Thrombopoietin receptor agonist |
| Main mechanism | Stimulates megakaryocyte development and platelet production |
| Main adult indications | Chronic liver disease-associated thrombocytopenia before a procedure and chronic ITP |
| Route of administration | Oral |
| Platelet response | Increase may begin within 3–5 days with the reference tablet product |
| Peak platelet response | Generally around 10–13 days with the reference tablet product |
| Monitoring | Regular platelet-count assessment |
| Important safety risk | Thrombotic and thromboembolic complications |
| Treatment supervision | Qualified healthcare professional |
Conclusion
Avatrombopag is an important treatment option for selected patients with thrombocytopenia. As a thrombopoietin receptor agonist, it stimulates platelet production through activation of receptors involved in megakaryocyte development and maturation.
Its established adult medical uses include thrombocytopenia associated with chronic liver disease in patients scheduled for a procedure and chronic immune thrombocytopenia in adults who have not responded adequately to previous treatment.
Clinical pharmacology information demonstrates that avatrombopag can increase platelet counts in a dose- and exposure-dependent manner. However, treatment response varies, and platelet-count monitoring is necessary to support appropriate treatment decisions.
Avapag 20 mg is identified on this website as a product containing avatrombopag. The clinical information presented here describes the active ingredient and established reference-product information. It does not establish Avapag-specific clinical trial results, bioequivalence, manufacturer identity or regulatory authorization.
Frequently Asked Questions About Avatrombopag Clinical Information
What is the pharmacological class of avatrombopag?
Avatrombopag belongs to the thrombopoietin receptor agonist class of medicines.
What is the mechanism of action of avatrombopag?
It activates thrombopoietin receptors in the bone marrow, stimulating megakaryocyte development and increasing platelet production.
How quickly can avatrombopag increase platelet counts?
With the reference tablet product, platelet increases have been observed within approximately 3–5 days, with peak effects generally around 10–13 days. Individual responses may vary.
What are the main clinical uses of avatrombopag?
Its established adult uses include chronic liver disease-associated thrombocytopenia before a scheduled procedure and chronic ITP in adults with an insufficient response to previous treatment.
Does avatrombopag directly replace platelets?
No. It stimulates the body’s platelet-production process rather than directly supplying platelets.
Why are platelet counts monitored during treatment?
Monitoring helps evaluate treatment response, guide dosage adjustments and identify excessive increases in platelet levels.
Can avatrombopag cause blood clots?
Thrombotic and thromboembolic complications are important safety risks associated with thrombopoietin receptor agonists.
Does avatrombopag cure chronic ITP?
No. It can help increase platelet counts in appropriate patients, but it does not necessarily eliminate the underlying immune condition.
Can other medicines affect avatrombopag?
Yes. Certain medicines that affect CYP2C9 and CYP3A4 enzyme pathways may change avatrombopag exposure and require clinical consideration.
Is Avapag clinically proven to be equivalent to Doptelet?
That cannot be established from the active ingredient and strength alone. Product-specific equivalence or bioequivalence requires appropriate supporting documentation.
Medical Disclaimer
The clinical information on this page is provided for educational purposes only. It is not intended to replace professional medical advice, diagnosis, prescribing information or treatment.
Avatrombopag should only be used under appropriate medical supervision. Patients should follow the prescribing instructions applicable to their specific product and country.